- Motley Fool•3 days ago
These biotech stocks could put on a clinic in your investment portfolio.
- American City Business Journals•3 days ago
Swiss drugmaker Santhera Pharmaceuticals has chosen Burlington as the site of its first U.S. office, joining a group of local companies that are developing treatments for Duchenne muscular dystrophy. Santhera said the facility in Burlington would be led by Todd Bazemore, its chief operating officer. Bazemore previously served as a top executive at Dyax, a Burlington biotech that was acquired by Lexington-based Shire in 2015.
- Benzinga•4 days ago
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT ) have declined sharply, with continued concerns around reimbursement and competition. The shares could appreciate going ahead, driven by “the ongoing eteplirsen ...
SRPT : Summary for Sarepta Therapeutics, Inc. - Yahoo Finance
Sarepta Therapeutics, Inc. (SRPT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||28.11 x 300|
|Ask||28.50 x 200|
|Day's Range||27.20 - 28.34|
|52 Week Range||8.00 - 63.73|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-5.37|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|